Wells Fargo raised the firm's price target on Novocure to $17 from $13.50 and keeps an Equal Weight rating on the shares. The firm notes Q1 results were ahead of expectations, leading to 2026 guidance raise. Wells is impressed by the early success of Optune Pax, which now has 83 active patients, and believes that U.S. Pax uptake could be closer to glioblastoma adoption curve than the muted lung cancer roll out.
